{
    "nct_id": "NCT01948791",
    "title": "16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT)",
    "status": "COMPLETED",
    "last_update_time": "2016-12-20",
    "description_brief": "To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "The Intention analysis set consists of 165 patients who received at least 1 treatment \\& had at least 1 assessment on primary efficacy variables.",
            "recruitmentDetails": "222 patients were screened/enrolled to this study but 41 did not receive study drug.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "ENA713",
                    "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "222"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "151"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "71"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "12"
                                }
                            ]
                        },
                        {
                            "type": "Lack of Efficacy",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                }
                            ]
                        },
                        {
                            "type": "Management issues",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Others",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                }
                            ]
                        },
                        {
                            "type": "Screening failure",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "35"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "Subjects who received at least one treatment, and had at least one post-baseline assessment on primary efficacy variables.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "ENA713",
                    "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "165"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "69.6",
                                            "spread": "8.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Gender",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "101"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "64"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)",
                    "description": "The Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) was used to measure change in cognitive function. Alzheimer's disease assessment scale (ADAS) is a scale to measure specific cognitive and behavior disorders in Alzheimer disease (AD) patients. The Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) provides a total score range 0-70, and consists of 11 items with lower score indicating lighter impairment and higher total scores indicating more impairment. A negative change score indicates improvement from baseline. Two-sided 95% CI of the difference in the means between baseline and post-baseline values were calculated.",
                    "populationDescription": "The Per Protocol (PP) population included all patients who had been enrolled to receive treatment, and who had received at least 1 dose of study drug, had 1 baseline assessment \\& at least 1 post-baseline efficacy assessment for primary efficacy variable within the Week 16 visit window, and had no major protocol violations.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline, Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "ENA713",
                            "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "151"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.0",
                                            "lowerLimit": "-3.0",
                                            "upperLimit": "1.1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000"
                            ],
                            "groupDescription": "The hypothesis to test the non-inferiority of post-baseline change in ADAS-Cog from baseline was: H0: \u03bcP - \u03bcB \u2265 1.40, Ha: \u03bcP - \u03bcB \\< 1.40 where \u03bcP and \u03bcB are the ADAS-Cog score (actual) at 16 weeks of Rivastigmine treatment and the baseline ADAS-Cog score (actual), respectively.",
                            "testedNonInferiority": true,
                            "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE",
                            "nonInferiorityComment": "If the upper limit of the 95% confidence interval of the mean difference between the baseline score and post-baseline score falls on the left of MeanP-MeanB+1.40, the post-baseline noninferiority to baseline can be concluded. If the upper limit of the 95% confidence interval of the mean difference between the baseline score and post-baseline score falls on the left of 0, superiority can be concluded.",
                            "pValue": "<0.001",
                            "statisticalMethod": "t-test, 1 sided"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score",
                    "description": "ADCS-ADL is a scale based on caregiver's assessment of patient's activities of daily life. It is used in clinical studies on dementia \\& consists of 23 items and is designed to assess patient's basic \\& instrumental activities of daily life, such as the abilities necessary for personal care, communicating \\& interacting with other people, maintaining a household, conducting hobbies \\& interests, \\& making judgments \\& decisions. Response to each item is obtained by interview with the caregiver. The basic activities of daily life domain includes mandatory options for best response, or \"yes\" or \"no\" questions with separate sub-questions. Higher score \\& more \"yes\" answers indicate better level of self-care of patient. Therefore the higher the total score is, the better the patient's functions. The total score is the sum of the scores of all the items \\& sub-questions,\\& ranges from 0 to 78. Two-sided 95% CI of the difference in the means between baseline and post-baseline values were calculated.",
                    "populationDescription": "The Per Protocol (PP) population included all patients who had been enrolled to receive treatment, had received at least 1 dose of study drug, had 1 baseline assessment \\& at least 1 post-baseline efficacy assessment for primary efficacy variable within the Week 16 visit window \\& had no major protocol violations.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline, Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "ENA713",
                            "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "151"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.9",
                                            "lowerLimit": "-0.5",
                                            "upperLimit": "2.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Mini-Mental State Examination (MMSE)",
                    "description": "MMSE was used to determine patient's eligibility to participate, is an easy \\& practical screening test to identify cognitive disorders. Test consists of 2 parts: language (time orientation, registration \\& attention) \\& performance (recall, response to written/verbal commands, writing ability \\& reproduction of complex polygons); total score range: 0-30; higher score = better function. Positive change score = improvement from baseline. To meet eligibility criteria, patient's MMSE total score at screening had to be 10-26 (inclusive). Interpretation of MMSE by 4 methods: Single Cut0ff: \\<24=abnormal; Range: \\<21=Increased odds of dementia; \\>25=Decreased odds of dementia; Education: 21- abnormal for 8th grade education, \\<23=abnormal for high school education, \\<24=abnormal for college education; Severity: 24-30=no cognitive impairment, 18-23=mild cognitive impairment, 0-17=severe cognitive impairment. 2-sided 95% CI of difference in means between baseline \\& post-baseline values were calculated",
                    "populationDescription": "The Per Protocol (PP) population included all patients who had been enrolled to receive treatment, had received at least 1 dose of study drug, had 1 baseline assessment \\& at least 1 post-baseline efficacy assessment for primary efficacy variable within the Week 16 visit window \\& had no major protocol violations.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline, Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "ENA713",
                            "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "151"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.3",
                                            "lowerLimit": "-0.4",
                                            "upperLimit": "0.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Score",
                    "description": "This scale assesses a larger scope of the behavior problems/disorders experienced in dementia patients, and identifies the frequency \\& severity of the behavior disorders, \\& allows rapid assessment using screening questions. 10 questions in behavior domain \\& 2 in autonomic nervous system domain were assessed by the investigator interviewing with the caregiver. The NPI-12 total score is the total score of the 12 items, among which the score for each domain is the product of frequency (range: 1-4 points) and severity (range: 1-3 points). The highest score for each domain is 12 points and all the domains have the same weight. Therefore the range of NPI-12 total score is 0-144 points. The NPI-10 total score is the total score of the first 10 items 0-120, which constitute the original form of this scale. A higher NPI total score indicates more severe behavior disorder. Two-sided 95% CI of the difference in the means between baseline and post-baseline values were calculated.",
                    "populationDescription": "The Per Protocol (PP) population included all patients who had been enrolled to receive treatment, had received at least 1 dose of study drug, had 1 baseline assessment \\& at least 1 post-baseline efficacy assessment for primary efficacy variable within the Week 16 visit window \\& had no major protocol violations.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline, Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "ENA713",
                            "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "151"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "NPI-10",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.6",
                                            "lowerLimit": "-5.3",
                                            "upperLimit": "-1.9"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "NPI-12",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-4.0",
                                            "lowerLimit": "-6.2",
                                            "upperLimit": "-1.9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Caregiver Burden Inventory (CBI) Score",
                    "description": "CBI, formulated by Novak and Guest in 1989, is a relatively complete and effective scale to measure caregiver burden that has been extensively adopted internationally. CBI has a total of 24 items in 5 domains, i.e., time dependency items (items 1-5), development items (items 6-10), physical health items (items 11-14), social relations items (items 15-18), and emotional heath items (items 19-24). Each item is scored on a 5-point scale based on the intensity of burden (0-4 points), so that the total score is 0-96, a higher score indicating heavier burden. It is a self-administered scale that takes about 10-15 minutes to complete. Two-sided 95% CI of the difference in the means between baseline and post-baseline values were calculated.",
                    "populationDescription": "The Per Protocol (PP) population included all patients who had been enrolled to receive treatment, had received at least 1 dose of study drug, had 1 baseline assessment \\& at least 1 post-baseline efficacy assessment for primary efficacy variable within the Week 16 visit window \\& had no major protocol violations.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline, Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "ENA713",
                            "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "151"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.4",
                                            "lowerLimit": "-3.1",
                                            "upperLimit": "0.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "3",
            "description": "The safety set consists of 181 patients who received at least one drug treatment and had post-baseline safety assessments.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "ENA713",
                    "description": "Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.",
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 181,
                    "otherNumAffected": 69,
                    "otherNumAtRisk": 181
                }
            ],
            "seriousEvents": [
                {
                    "term": "Arteriosclerosis coronary artery",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Ankle fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Brain contusion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Contusion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Patella fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Pneumocephalus",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Pulmonary contusion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Rib fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Skin abrasion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Skull fractured base",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Soft tissue injury",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Subcutaneous haematoma",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Osteoarthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Brain injury",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Subarachnoid haemorrhage",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Uterine prolapse",
                    "organSystem": "Reproductive system and breast disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Pleural effusion",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Venous thrombosis limb",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 181
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Abdominal discomfort",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 37,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 30,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Decreased appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 14,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 181
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 18.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 181
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "limitationsAndCaveats": {
                "description": "Of the total recruited subjects, 181 subjects received at least one drug treatment and there were post-baseline safety assessment. They were incorporated into the safety population."
            },
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data in the clinical trial."
            },
            "pointOfContact": {
                "title": "Study Director",
                "organization": "Novartis Pharmaceuticals",
                "phone": "862-778-8300"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "Exelon (rivastigmine)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests Exelon (brand name for rivastigmine) given by titration to a maximal tolerated dose (3 mg/day \u2192 12 mg/day) for 16 weeks in mild\u2013moderate AD. Rivastigmine is a cholinesterase inhibitor that increases acetylcholine and is used to improve cognitive symptoms in Alzheimer\u2019s disease rather than to clear amyloid or tau, so it fits the \"cognitive enhancer\" category. \ue200cite\ue202turn0search6\ue202turn0search4\ue201",
        "Act: Extracted details \u2014 drug: Exelon (rivastigmine); formulation/dosing in description: capsule titration from 3 mg/day up to 12 mg/day over 16 weeks (matches typical 3\u201312 mg/day dosing range). Mechanism/intent: symptomatic enhancement of cholinergic function (improves cognition/ADLs) rather than disease modification. \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Reflect: Classification check \u2014 fits definitions: not a biologic (rivastigmine is a small-molecule cholinesterase inhibitor), but its clinical role is symptomatic cognitive improvement rather than targeting core AD pathology for disease modification. Therefore the best category is \"cognitive enhancer.\" Note: rivastigmine inhibits acetylcholinesterase/butyrylcholinesterase and is indicated for symptomatic treatment of mild\u2013moderate AD; label and reviews state no evidence it alters underlying disease course. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Web search results (key sources used): Drugs.com dosing/label summary for Exelon (dosing/titration, max 12 mg/day). \ue200cite\ue202turn0search0\ue201; PubMed/Drug reviews describing rivastigmine mechanism as a (pseudo\u2011irreversible) cholinesterase inhibitor and symptomatic cognitive effects. \ue200cite\ue202turn0search3\ue201; Medthority / label summary noting mechanism, symptomatic effect and statement that it does not alter course of disease. \ue200cite\ue202turn0search4\ue201; PMC guideline review summarizing rivastigmine as a cholinesterase inhibitor improving cognition/ADLs. \ue200cite\ue202turn0search5\ue201; NCATS/drug info summary confirming Exelon = rivastigmine and clinical indications. \ue200cite\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests Exelon (rivastigmine), a cholinesterase inhibitor that increases synaptic acetylcholine to improve cognition and activities of daily living\u2014i.e., it modulates cholinergic neurotransmission rather than targeting amyloid, tau, or neuroinflammation. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Act: Extracted details \u2014 drug: Exelon (rivastigmine); dosing/titration described (targeting up to 12 mg/day) consistent with labeled oral capsule regimens; mechanism/intent: symptomatic enhancement of cholinergic signaling via inhibition of acetylcholinesterase and butyrylcholinesterase. Based on these facts, the most specific CADRO match is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Reflect: Confirmed classification \u2014 rivastigmine is a symptomatic cognitive enhancer (not disease\u2011modifying) that acts by augmenting neurotransmitter (acetylcholine) availability, which aligns with CADRO category D (Neurotransmitter Receptors). Evidence summaries and systematic reviews support symptomatic benefit but not disease modification. \ue200cite\ue202turn0search6\ue202turn0search3\ue201",
        "Web search results (key sources used): Drugs.com dosing/label summary for Exelon (shows titration and 3\u201312 mg/day range); PubMed reviews describing rivastigmine mechanism as a cholinesterase inhibitor; MIMS/other drug monographs describing AChE/BuChE inhibition; Cochrane review summarizing symptomatic benefits in mild\u2013moderate AD. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search8\ue202turn0search6\ue201"
    ]
}